Skip to main content
. 2020 Sep 29;6(3):e001297. doi: 10.1136/rmdopen-2020-001297

Table 1.

Main clinical signs and symptoms at GCA fast-track clinic referral

Total no. 354 (%) LRC no. 151 (%) IRC no. 137 (%) HRC no. 66 (%) P value Not GCA no. 265 (%) GCA no. 89 (%) P value
Headache
 Generalised 56 (15.8) 31 (20.5) 21 (15.3) 4 (6.1) 0.02 53 (20) 3 (3.4) 0.002
 Temporal, unilateral 110 (31.1) 41 (27.2) 43 (31.4) 26 (39.4) 0.2 73 (27.5) 37 (41.6) 0.01
 Temporal, bilateral 73 (20.6) 20 (13.2) 31 (22.6) 22 (33.3) 0.003 38 (14.3) 35 (39.3) <0.001
Scalp tenderness
 Unilateral 53 (15) 14 (9.3) 19 (13.9) 20 (30.3) 0.001 26 (9.8) 27 (30.3) <0.001
 Bilateral 51 (14.4) 11 (7.3) 16 (11.7) 22 (33.3) <0.001 22 (8.3) 29 (32.6) <0.001
Jaw claudication 70 (19.8) 11 (7.3) 25 (18.2) 34 (51.5) <0.001 23 (8.7) 47 (52.8) <0.001
PMR symptoms 134 (37.9) 38 (25.2) 61 (44.5) 35 (53) <0.001 93 (35.1) 41 (46.1) 0.043
Constitutional symptoms
 Single 63 (17.8) 18 (11.9) 24 (17.5) 21 (31.8) 0.003 37 (14) 26 (29.2) 0.001
 Combination 50 (14.1) 6 (4) 22 (16.1) 23 (34.8) <0.001 25 (9.4) 26 (29.2) <0.001
Visual disturbances
 Blurred vision 62 (17.5) 19 (12.6) 23 (16.8) 20 (30.3) 0.008 36 (13.6) 26 (29.2) 0.001
 Double vision 17 (4.8) 5 (3.3) 7 (5.1) 5 (7.6) 0.352 9 (3.4) 8 (9) <0.001
 Amaurosis 22 (6.2) 4 (2.6) 9 (6.6) 9 (13.6) 0.01 8 (3) 14 (15.7) <0.001
Vision loss type
 AION 16 (4.5) 1 (0.7) 5 (3.6) 10 (15.1) <0.001 2 (0.8) 14 (15.7) <0.001
 CRAO 8 (2.3) 1 (0.7) 4 (2.9) 3 (4.5) 0.126 3 (1.1) 5 (5.6) 0.026
 AION+CRAO 3 (0.8) 0 2 (1.5) 1 (1.5) 0.308 0 3 (3.4) 0.015
Mean CRP level (mg/L) 38 (±51) 15 (±25) 42 (±50) 82 (±64) <0.001 28 (±45) 68 (±56) <0.001

AION, anterior ischaemic optic neuritis; CRAO, central retinal artery occlusion; CRP, C reactive protein; GCA, giant cell arteritis; HRC, high-risk category; IRC, intermediate-risk category; LRC, low-risk category; PMR, polymyalgia rheumatica.